ALCL 99

Main objectives of the trial: to improve eventfree and overall survival
Second objective: to verify the criteria for stratification

Classification of therapeutic groups and treatment plan

The very rare patients with isolated skin disease (completely resected or not) will not receive any chemotherapy. This requires a very complete evaluation. Such patients should be discussed with the study coordinator to confirm the very cautious « wait and see » decision.

Low risk group (LR): Stage I disease completely resected

All patients receive the prephase and 3 blocks Chemotherapy (AM, BM AM)

Group SR (Standard risk group)

The randomisation has been closed since 22/05/2006. All patients receive the prephase and treatment arm 3 with MTX 3g/m² and 6 blocks of Chemotherapy (3 x AM and 3 x BM alternating).

Group HR (High risk group)

Randomisation has been closed since 22nd of May 2006. All patients in trial should be treated according to arm 3 with 3g MTX/m² without intrathecal injections and without Vinblastine.

• ALCL diagnosed by local pathologist
• Slides available for national pathology review for all cases. If the local pathologist refuses to send slides (either cytological or histological) for central review, the patient is not eligible except in the situation where the presence of t(2;5) is proven.
• No previous treatment (except for corticosteroids which should not have been given for more than 8 days).
• Age < 22 years.